WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant

Leuk Res. 2021 Sep:108:106587. doi: 10.1016/j.leukres.2021.106587. Epub 2021 Apr 30.

Authors

Alessandra Sperotto¹, Michele Gottardi², Anna Candoni³, Eleonora Toffoletti³, Roberta De Marchi², Giuseppe Petruzzellis³, Umberto Pizzano³, Renato Fanin³

Affiliations

¹ Hematology and Transplant Center Unit, Dipartimento di Area Medica (DAME), Udine University Hospital, Italy. Electronic address: [email protected].
² Onco Hematology, Department of Oncology, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy.
³ Hematology and Transplant Center Unit, Dipartimento di Area Medica (DAME), Udine University Hospital, Italy.

PMID: 34020318
DOI: 10.1016/j.leukres.2021.106587

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Combined Modality Therapy
Decitabine / therapeutic use*
Female
Gene Expression Regulation, Neoplastic
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / etiology
Neoplasm Recurrence, Local / pathology
Prognosis
Transplantation, Homologous
WT1 Proteins / genetics
WT1 Proteins / metabolism*

Substances

Antimetabolites, Antineoplastic
Biomarkers, Tumor
WT1 Proteins
WT1 protein, human
Decitabine